Company Overview

Genmab A/S is a leading Danish biotechnology company dedicated to the discovery, development, and commercialization of differentiated antibody therapeutics for the treatment of life-threatening diseases. Founded in February 1999 by Florian Schönharting and headquartered in Copenhagen, Denmark, the company is at the forefront of developing innovative treatments for cancer, infectious diseases, rheumatoid arthritis, and other conditions. Genmab is dual-listed, with its shares traded on the Copenhagen Stock Exchange in Denmark and its American Depositary Receipts (ADRs) traded on the NASDAQ in the US. As of September 12, 2025, Genmab's market capitalization stood at $17.85 billion.

The company specializes in creating human and therapeutic antibodies. Genmab has successfully developed and secured approval for eight of its antibodies (both monoclonal and bispecific), which are incorporated into eight marketed products targeting significant cancer indications and autoimmune diseases.

Core Business and Revenue Structure

Genmab's revenue streams are primarily derived from royalties, which constitute approximately 80.6% of its net sales. Additional income comes from research and development activities (9.3%) and other sources, mainly from partnership agreements (10.1%). The company employs a dedicated team of 2,639 individuals and maintains a significant international presence through subsidiaries located in the Netherlands, the United States, Japan, Germany, and China.

Key Products and Pipeline

Marketed Products

Genmab's portfolio features several highly successful products:

- EPKINLY™ and TEPKINLY™: Approved for adult patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLCL), large B-cell lymphoma, and follicular lymphoma.

- Tivdak®: Indicated for adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after chemotherapy.

- DARZALEX® (daratumumab): A major contributor to Genmab's revenue through significant royalty income.

Development Pipeline

As of the close of 2024, Genmab boasts an extensive pipeline comprising over 20 products in various clinical development phases and an additional 20 products in preclinical development. The company is actively advancing the development of several promising candidates, including:

- Amivantamab: Targeted for recurrent/metastatic head and neck cancer and advanced or metastatic colorectal cancer.

- Amlenetug: Under development for multiple system atrophy.

- Inclacumab: Being developed for the treatment of vaso-occlusive crises in sickle cell disease.

- Mim8: Investigated for its efficacy in hemophilia A.

Strategic Partnerships

Genmab has established robust collaboration agreements with numerous leading global pharmaceutical and biotechnology companies. These strategic partnerships are crucial for advancing its pipeline and expanding market reach. Key collaborators include:

- AbbVie Inc.

- Pfizer Inc.

- BioNTech SE

- Johnson & Johnson

- Novartis International AG

- Medarex, Inc.

- ADC Therapeutics SA

- Bristol Myers Squibb Corporation

- Lundbeck A/S

- Amgen Inc.

- Immatics

- Novo Nordisk A/S

- CureVac AG

- argenx

Recent Financial Performance

Q2 2025 Results

Genmab announced strong financial results for the second quarter of 2025. The company reported an Earnings Per Share (EPS) of $0.542, a significant 39.4% increase above the forecast of $0.3888. Revenue for the quarter reached $925 million, exceeding predictions by 3.54%. Genmab demonstrated robust financial performance in Q2 2025, with total revenue growing by 19% in the first half of the year.

Key Q2 2025 metrics include:

- Revenue: $925 million, a 19% increase year-over-year.

- Earnings per Share (EPS): $0.542, representing a 39.4% beat on forecasts.

- Operating Profit: Increased by 56%.

- Net Profit: $531 million.

Financial Position and Outlook

Genmab concluded the first half of 2025 with approximately $3 billion in cash reserves, providing substantial financial flexibility for future growth and expansion initiatives. The company maintains an exceptional financial position, characterized by a current ratio of 5.34 and a minimal debt-to-equity ratio of 0.03, underscoring its ability to support strategic objectives.

For the full fiscal year 2025, Genmab has revised its revenue guidance upward to a range of $3.5 billion to $3.7 billion, projecting an approximate 15% growth. The company anticipates an operating profit between $1.1 billion and $1.4 billion. Genmab's projected 2025 revenue is predominantly driven by DARZALEX® royalties, estimated at approximately $2.2 billion (midpoint), based on projected DARZALEX® 2025 net sales ranging from $12.6 billion to $13.4 billion.

Technology Platform and Innovation

Genmab's core technology leverages a platform licensed from Medarex, which utilizes transgenic mice to generate fully human, high-affinity antibodies. This approach is designed to produce IgG antibodies that closely resemble human proteins, thereby reducing the likelihood of eliciting allergic reactions and other adverse side effects often associated with less humanized antibody types.

The company employs proprietary technology platforms, including DuoBody®, HexaBody®, DuoHexaBody®, and HexElect®, to fuel its robust pipeline of advanced antibody therapeutics.

Recent Corporate Developments

In April 2024, Genmab announced its strategic intent to acquire ProfoundBio for $1.8 billion. This acquisition is expected to bolster Genmab's pipeline, particularly in antibody-drug conjugates. Concurrently, the EPCORE FL-1 study met its dual primary endpoints for progression-free survival and overall response rate, paving the way for global regulatory submissions.

Leadership

Dr. Jan Van de Winkel, a co-founder of Genmab, serves as its President and Chief Executive Officer (CEO). Since the company's inception in 1999, he has played a pivotal role, previously holding the position of Chief Scientific Officer (CSO) and concurrently leading research and development efforts.

Genmab stands as a preeminent force in the biotechnology sector, characterized by a formidable financial foundation, cutting-edge antibody technology platforms, and a deep pipeline of potential treatments for cancer and autoimmune diseases. The company's dual-listing strategy and its extensive network of strategic partnerships position it advantageously for sustained growth within the dynamic global biotechnology market.